The first annual Drug Discovery and Development Symposium for Pulmonary Hypertension

PVRI Member Authors: John H. Newman

Currently, clinical trials in pulmonary hypertension (PH) are limited by the absence of mechanistic arms, by weak end points, by failure to capture biological material, and by the inability to restudy data. Clinical studies in PH would be markedly enhanced by a consortium approach that utilizes the expertise of academic medicine, the therapeutic initiatives of the pharmaceutical industry, and study design from funding agencies interested in biological mechanisms. New approaches to PH are emerging from basic studies of signaling, management of the genome, and preservation of metabolic function and from testing of newer molecules that have efficacy in oncologic and inflammatory illnesses.

Published in:

Pulmonary Circulation Vol 4: No 4 cover image

December 2014

Pulmonary Circulation Vol 4: No 4

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI